Madrid, Dec. 22, 2021 /PRNewswire/ -- PharmaMar
(MSE: PHM) has announced today a new license and commercialization
agreement with the Eczacıbaşı Pharmaceuticals Marketing Co. to
commercialize the anticancer drug lurbinectedin in Turkey.
Under the terms of the agreement, PharmaMar will receive a
non-disclosed upfront payment and will be eligible for additional
remunerations, including regulatory and sales milestone payments.
PharmaMar will retain production rights and will sell the product
to Eczacıbaşı for its clinical and commercial use.
Eczacıbaşı will pursue the marketing authorization in
Turkey and will have the right to
commercialize the product on an exclusive basis, upon approval. In
addition, a Named Patient Basis program is planned to be launched
in Turkey via TEB (Turkish
Pharmacy Association) to make lurbinectedin accessible to relapsed
Small Cell Lung Cancer (SCLC) patients, who are unable to enter
clinical trials and to whom no alternative treatments are
available.
Luis Mora, General Manager
of PharmaMar's Oncology and Virology Business Units, said: "This
is the second agreement we have signed with Eczacıbaşı. We have
great confidence in their team and we are confident that, if
approved, they will bring lurbinectedin to SCLC patients in
Turkey."
Basbug Oke, General Manager of Eczacıbaşı Pharmaceuticals
Marketing Co., stated that "We are passionate about launching
innovative medicines in Turkey and
PharmaMar is a unique partner given their expertise in research and
development. Lung cancer is the leading cause of cancer
mortality accounting 37.000 deaths per year in Turkey and we believe lurbinectedin will be an
important treatment option for Small Cell Lung Cancer patients. We
look forward to working with PharmaMar closely to expeditiously
bring lurbinectedin to patients in Turkey."
Lurbinectedin was granted accelerated approval by FDA (Food and
Drug Administration) for the treatment of relapsed metastatic Small
Cell Lung Cancer in 2020. In addition, in 2021, lurbinectedin has
received marketing approval in the United
Arab Emirates, Canada,
Australia and Singapore.
About lurbinectedin
Lurbinectedin (Zepzelca®), also known as PM1183, is
an analog of the marine compound ET-736 isolated from the sea
squirt Ecteinacidia turbinata in which a hydrogen atom has
been replaced by a methoxy group. It is a selective inhibitor of
the oncogenic transcription programs on which many tumors are
particularly dependent.
Media Contact:
Lara
Vadillo – Communication Director lvadillo@pharmamar.com.
Mobile: +34 669 47 18 03
Miguel Martínez-Cava – Communication Manager
mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000